Table 2. Anti-H. pylori IgG titers and seroprevalence according to self-reported treatment history for H. pylori among ever-infected subjects in the JPHC-NEXT Study.
| Untreateda | Years from treatmenta | P-valueb | |||
|
|
|
||||
| <1Y | 1–5Y | 6Y+ | |||
| All | n = 22,420 | n = 1,100 | n = 2,889 | n = 2,287 | |
| H. pylori antibody titer, IQR, U/mL | 34.0 (14.0–48.6) | 7.9 (4.0–16.4) | 4.0 (3.0–7.2) | 2.9 (2.9–4.5) | <0.01 |
| <3 U/mLc, n (%) | 490 (2.2) | 183 (16.6) | 982 (34.0) | 1,274 (55.7) | <0.01 |
| 3–<10 U/mLc, n (%) | 3,700 (16.5) | 466 (42.4) | 1,444 (50.0) | 761 (33.3) | |
| ≥10 U/mLc, n (%) | 18,230 (81.3) | 451 (41.0) | 463 (16.0) | 252 (11.0) | |
|
| |||||
| Men | n = 9,583 | n = 484 | n = 1,429 | n = 1,361 | |
| H. pylori antibody titer, IQR, U/mL | 32.8 (13.7–45.0) | 7.6 (4.3–14.3) | 3.9 (3.0–6.8) | 2.9 (2.9–4.5) | <0.01 |
| <3 U/mLc, n (%) | 197 (2.1) | 80 (16.5) | 502 (35.1) | 757 (55.6) | <0.01 |
| 3–<10 U/mLc, n (%) | 1,562 (18.4) | 221 (45.7) | 721 (50.5) | 454 (33.4) | |
| ≥10 U/mLc, n (%) | 7,824 (81.6) | 183 (37.8) | 206 (14.4) | 150 (11.0) | |
|
| |||||
| Women | n = 12,837 | n = 616 | n = 1,460 | n = 926 | |
| H. pylori antibody titer, IQR, U/mL | 36.0 (14.3–51.1) | 8.0 (3.9–18.5) | 4.2 (3.0–7.6) | 2.9 (2.9–4.5) | <0.01 |
| <3 U/mLc, n (%) | 293 (2.3) | 103 (16.7) | 480 (32.9) | 517 (55.8) | <0.01 |
| 3–<10 U/mLc, n (%) | 2,138 (16.7) | 245 (39.8) | 723 (49.5) | 307 (33.2) | |
| ≥10 U/mLc, n (%) | 10,406 (81.1) | 268 (43.5) | 257 (17.6) | 102 (11.0) | |
IQR, interquartile range; n, number.
aSubjects were classified according to their self-reported treatment history for H. pylori as follows: none: untreated; treated less than 1 year ago: <1Y; treated 1 to 5 years ago: 1–5Y; and treated 6 or more years ago: 6Y+.
bChi-square test for categorical variables and unadjusted quantile regression to compare median values.
cH. pylori antibody titer of <3 U/mL, ≥3 to <10 U/mL, and ≥10 U/mL were defined as low-negative, high-negative and positive, respectively.